Registration Options

Activity Dates: 03/06/2019 - 09/10/2019

Target Audience

This self-study activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and health care providers seeking advanced education in patient management, disease state management, information management, and health policy and practice management in the field of psychiatric pharmacy.


The articles selected by CPNP Recertification Editorial Board for the Literature Analysis are based on a 7-year curriculum. This curriculum is developed using the Board of Pharmaceutical Specialties' Content Outline for the Psychiatric Pharmacy Specialty Certification Examination as a guideline. Since CPNP became the sole BCPP Recertification provider in 2008, the articles are chosen to cover the three content domains - Domain I: Patient Management, Domain 2: Information Management, Domain 3: Health Policy and Practice Management.

The Literature Analysis is a self-study, online only, application-based continuing pharmacy education (CPE) activity that releases March 6, 2019. An application-based CPE activity requires that participants apply the information learned. The examination for this product often features case studies requiring that the participant apply the principles learned through the readings. The Literature Analysis includes:

  • Electronic access to all required journal articles needed to prepare for the online assessment.
  • For pharmacists, 10 hours of ACPE credit and 10 hours of BCPP Recertification credit achieved by successfully completing the online CPNP recertification examination.
  • Access to the CPNP testing center with exam submission due by or on September 6, 2019.

Course Requirements

To satisfactorily complete the Literature Analysis and receive 10 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:

  1. Abide by a confidentiality and honesty statement requiring individual completion of the recertification education.
  2. Complete an online assessment on or before the deadline of September 6, 2019.
  3. Meet the minimum passing score to be determined by a panel of experts within four (4) weeks following the exam deadline.
  4. Partial credit is not available for individual topics within the Literature Analysis programming; it is either all 10 hours of Literature Analysis programming credit or none.

You will proceed through the following steps to satisfactorily complete this course:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Complete the pre-test before starting the activity.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • Wait for the official review of exam questions within 4 weeks following the closing date.
  • Receive a passing grade (76%).
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Participants successfully passing the required assessment/examination will obtain both ACPE and BCPP recertification credit. Credit is awarded in the calendar year the assessment is completed. ACPE credit is reported through CPE Monitor within days of examination submission, while BCPP recertification credit is reported to BPS within 6 weeks after the examination deadline.

Learning Objectives

Article Number Topic Article and Learning Objectives
1 Alcohol Use Disorders

The American Psychiatric Association. (2018). Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder. doi:10.1176/appi.books.9781615371969. Pages 5-46 only.

  1. Evaluate recommendations for the use of quantitative behavioral measurements and physiological biomarkers in patients with known or suspected alcohol use disorder. 
  2. Develop policies and processes to optimize the management of patients with alcohol use disorder.
  3. Apply pharmacologic treatment recommendations to design an individualized treatment plan for patient cases encountered in clinical practice.
  4. Analyze recommendations regarding special populations with alcohol use disorder (i.e., pregnant or breast-feeding women, renal/hepatic impairment, concurrent opioid use).
2 Personality Disorders

Bozzatello P, Rocca P, Uscinska M, Bellino S. Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial CNS Drugs.2017;31(9):809-819.

  1. Evaluate the usefulness of asenapine and olanzapine in the treatment of borderline personality disorder (BPD)-specific symptom clusters.
  2. Distinguish the presence and intensity of adverse effects from asenapine and olanzapine in the treatment of BPD symptom clusters.
  3. Compare the risks and benefits of using asenapine or olanzapine in the treatment of BPD-specific symptoms.
3 First Episode Schizophrenia

Kishi, Taro et al. Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials. Psychiatry Res. 2016 Dec 30;246:750-755. doi: 10.1016/j.psychres.2016.10.053. Epub 2016 Nov 3.

  1. Analyze the use of long-acting injectable antipsychotics for the management of recent-onset psychosis.
  2. Design a pharmacotherapy plan using long-acting injectable antipsychotic medication for the management of recent-onset psychosis.
  3. Contrast adverse event occurrence between long-acting injectable and oral antipsychotics for the management of recent-onset psychosis.
4 First Episode Schizophrenia

Wils, Regitze Sølling et al. Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res. 2017 Apr;182:42-48. doi: 10.1016/j.schres.2016.10.030. Epub 2016 Oct 27.

  1. Examine patient outcomes ten years after first-episode psychosis.
  2. Predict remission of psychotic symptoms ten years after first-episode psychosis.
  3. Select patients more likely to be remitted-off-antipsychotics at ten years after first-episode psychosis.
5 Movement Disorders

Alessandra Spadaro, Jamie Kellar, Gary Remington, Beth Sproule, Mayce Al-Sukhni,, Albert Chaiet. Evaluation of an Educational Program for Clinical Pharmacists to Conduct Standardized Assessments for Medication-Induced Movement-Related Disorders. Can J Hosp Pharm. 2015 May-Jun;68(3):258-64.

  1. Identify the impact of training on pharmacists’ ability to use ratings scales to accurately assess movement disorders.
  2. Contrast limitations of video and live movement disorder training for pharmacists.
  3. Evaluate the study design with regard to generalizability of results.

Paydary, K., Akamaloo, A., Ahmadipour, A., Pishgar, F., Emamzadehfard, S. and Akhondzadeh, S. (2016), N‐acetylcysteine augmentation therapy for moderate‐to‐severe obsessive–compulsive disorder: randomized, double‐blind, placebo‐controlled trial. J Clin Pharm Ther, 41: 214-219. doi:10.1111/jcpt.12370

  1. Explain the role of glutamate in the pathophysiology of obsessive-compulsive disorder.
  2. Evaluate the safety of N-acetylcysteine in the treatment of obsessive-compulsive disorder.
  3. Determine the efficacy of N-acetylcysteine in the treatment of obsessive-compulsive disorder.
7 Developmental Disorders

Bigby, C., Frawley, P. and Ramcharan, P. (2014), Conceptualizing Inclusive Research with People with Intellectual Disability. J Appl Res Intellect Disabil, 27: 3-12. doi:10.1111/jar.12083

  1. Compare the different approaches to inclusive research in the intellectually disabled population.
  2. Choose the most appropriate method of inclusive research for individuals with intellectual disabilities when given the study design.
  3. Evaluate when an individual with an intellectual disability is appropriate for inclusion in a research study based on the patient characteristics or study design.
8 Pharmacogenomics of Mood Disorders

Amare AT, Schubert KO, Baune BT. Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry. The EPMA Journal. 2017;8(3):211-227.

  1. Analyze the relationship between genetic polymorphisms and the treatment of mood disorders.
  2. Interpret pharmacogenetic test results for a patient with a mood disorder.
  3. Recommend candidate genes to test for treatment response or tolerability in patients with mood disorders.
9 Applicability and Generalizability of Research Findings

Blanco C, Hoertel N, Franco S, Olfson M, He J, Lopez S, Gonzalez-Pinto A, Limosin F, Merikangas K. Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder. Pediatrics. 2017;140(6):e20161701.

  1. Apply exclusion criteria commonly used in adolescent pharmacologic and psychotherapy trials for major depressive disorder.
  2. Examine rationale for commonly used exclusion criteria in adolescent clinical trials for major depressive disorder.
  3. Assess the generalizability of randomized controlled trials on pharmacologic and psychotherapy interventions to adolescents with major depressive disorder.

Continuing Education Credit and Disclosures

Activity Dates: 03/06/2019 - 09/10/2019
ACPE Contact Hours: 10
ACPE Number: 0284-0000-19-001-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Literature Analysis product is an application-based program approved for 10 hours of ACPE credit. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed.

Board Certified Psychiatric Pharmacists (BCPPs) may also receive 10 hours of BCPP Recertification Credit for the Literature Analysis upon successful completion of an online examination.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.